Showing results (1-10 of 264) with videos related to
Sort By:
Pageof 27
Cancer Letters|July 26, 2003
The MYCN oncoprotein as a drug development targetXiaohong Lu, Andrew Pearson, John LunecCancer Letters|July 26, 2003
Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?Debbie Scott, Joanna Elsden, Andrew Pearson, et al.Oncology Reports|February 22, 2008
Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerizationXiaohong Lu, Peter K Vogt, Dale L Boger, et al.The Prostate|April 19, 2007
Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cellsIan R Logan, Hesta V McNeill, Susan Cook, et al.Cell Cycle (Georgetown, Tex.)|December 19, 2006
The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damageEmma Bell, Rakesh Premkumar, Jane Carr, et al.Gene|October 6, 2005
Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogeneHuiling Liang, John LunecExpert Review of Anticancer Therapy|June 7, 2008
Molecular pathology and potential therapeutic targets in soft-tissue sarcomaRadha Todd, John LunecNucleic Acids Research|March 20, 2009
Heat shock factor-1 modulates p53 activity in the transcriptional response to DNA damageIan R Logan, Hesta V McNeill, Susan Cook, et al.Cancers|January 11, 2022
Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53<sup>WT</sup> Uterine LeiomyosarcomaVictoria Chamberlain, Yvette Drew, John LunecCancer Metastasis Reviews|June 19, 2012
Non-glucose metabolism in cancer cells--is it all in the fat?Swethajit Biswas, John Lunec, Kim BartlettPageof 27